Verluma Nofetumomab Merpentan (Fragment). Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed.

Slides:



Advertisements
Similar presentations
CLINICAL USE OF SPECT-CT IN BREAST & PROSTATE CANCERS
Advertisements

Frank P. Dawry Thyroid Cancer Therapy Radioactive Iodine (I-131)
Frank P. Dawry.
Receptor-guided tumor targeting for localization, staging and treatment.
Metastatic bone tumor Maher swaileh.
Lesson 2 Ultraviolet (UV) rays can put a person at risk for developing cancer. How does each item in the picture help protect you from UV rays? Cancer.
Frank P. Dawry LYMPHOSCINTIGRAPHY Sentinel node localization in Melanoma.
The scientific unit of measurement for radiation dose, commonly referred to as effective dose, is the millisievert (mSv)
The Diagnostic Applications of Labeled WBCs Using 111In and 99mTc
PHYSICS IN NUCLEAR MEDICINE: QUANTITAITVE SPECT AND CLINICAL APPLICATIONS Kathy Willowson Department of Nuclear Medicine, Royal North Shore Hospital University.
Brain Scan Imaging MRI, CAT, PET Imaging Interpreting Functions of the Brain through Imaging – Activity Case Study – Professional Sports and Head Trauma.
RADIOPHARMACY Diagnostic Nuclear Medicine 3 continue 6.
Radioisotopes in Medicine
AN INTRODUCTION TO PET-CT SCANNING Ray Murphy Chair – MCCN Partnership Group.
Radionuclide methods in oncology Otto Lang, MD, PhD Otakar Bělohlávek, MD, CSc Dept Nucl Med Charles Univ, 3rd Med Fac Materials for medical students.
Radiotherapy for Kidney cancer
Nuclear Medicine By: Amanda Taulanga 3B.
Melanoma Olivia Wilson.
Bladder Cancer Ishan Parikh. Where and What? The bladder… -stores urine received from the kidneys -is about the size of a pear when empty -is a very elastic.
Introduction to Nuclear Medicine
Nuclear Medicine. The History Henri Becquerel 1896-Discovered mysterious “rays” Nobel Prize Marie Curie named mysterious rays “radioactivity”
The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99 mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT,
Dual-time point 18F-FDG PET/CT scan: is it always working?
In the name of God Isfahan medical school Shahnaz Aram MD.
WORK UPS. Ultrasound method of choice for the differentiation of cysts from solid masses and for guidance in interventional procedures. Benign: – solid.
RADIOPHARMACY Diagnostic Nuclear Medicine 4 continue 7.
WHAT ARE THE RISK FACTORS FOR LUNG CANCER? SMOKING.
Cancer By: Erionne. What is Cancer Cancer begins in your cells, which are the building blocks of your body. Normally, your body forms new cells as you.
9 Radionuclide therapy.
radio-iodinated metaiodobenzylguanidine (123I-MIBG)
Palliative Care Eyad Al-Saeed, MD,FRCPC Consultant Radiation Oncology Prince Sultan Hematology Oncology Center.
Octreoscan Radiolabled Somatostatin Analog. What Is Somatostatin?  Somatostatin is a naturally occurring neuropeptide found in the hypothalamus that.
Technically Speaking – It’s All About Quality Gee Mom How Did You Get That Artifact?
NeoTect Tc99m Depreotide Injection. NeoTect  Approved by the FDA - August 3, 1999  Used in Imaging Pulmonary Masses  Normal activity in high concentrations.
Introduction to. RADIATION  Potentially harmful ray used for diagnostic or therapeutic purposes.
By Taylor Fischer, Hayden Howrie, Desirae Reimer, and Kassidy Urichuk
Ultraviolet (UV) rays can put a person at risk for developing cancer. How does each item in the picture help protect you from UV rays? Cancer.
VCU NMT Program Adrenal Scintigraphy Aldosteronism Addison’s Cushing’s Virilizing Adenomas Pheochormocytomas Neuroblastomas Adrenal Cortical Pathologies:
Nuclear medicine Basic principles.
Introduction to NM Omima Adam NMT 231. What is nuclear medicine NM Is the branch of medicine that uses radiation and nuclear properties of radionuclide's.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.
Inaya medical science college Introduction To Nuclear Medicine Technology RAD364 L: Aya Ahmed Abd alrahium saeed MSC &BSC Nuclear medicine.
CANCER.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
Nuclear Medicine in Gastrointestinal System
(Approved investigational)
CANCER.
PET Applications in Oncology 2015/2016
CT and PET imaging in non-small cell lung cancer
Radio Iodine Therapy In Cancer Thyroid
Example of a normal bone scan, presented as an anterior and a posterior body image. The “hot spot” at the elbow is the injection site. The bladder is also.
Professor of Nuclear Medicine Cairo University, Egypt
Globular Protein Made of amino acid chains
Professor of Nuclear Medicine Cairo University, Egypt
by: Prof.Dr. Hosna Moustafa Cairo University, Egypt
Treatment for Cancer.
Applications of Diagnostic Imaging Nuclear Medicine
Advanced Clinical Practice in Nuclear Medicine
Radiolabled Somatostatin Analog
Tc99m Depreotide Injection
Nofetumomab Merpentan (Fragment)
VCU NMT Program Adrenal Scintigraphy
VCU NMT Program Adrenal Scintigraphy
Ultraviolet (UV) rays can put a person at risk for developing cancer.
Radioisotopes in Medicine
Technically Speaking – It’s All About Quality
The Diagnostic Applications of Labeled WBCs Using 111In and 99mTc
Treatment Overview: The Multidisciplinary Team
Radiolabled Somatostatin Analog
Presentation transcript:

Verluma Nofetumomab Merpentan (Fragment)

Indications For the detection and staging of previously untreated small cell lung cancer. It must be confirmed via biopsy confirmed

Radiopharmaceutical and Dose 5-10 mg Verluma labeled with mCi Tc99m in 15-20ml Administered over 3-5 minutes Kit is good for 6 hours

Method of Localization and Excretion Recognizes glycoprotein cancer associated antigen expressed on a variety of tumors. 64% renal clearance in 22 hours –Secondary route hepatobiliary

Precautions and Patient Prep Possibility of HAMA response Well Hydrate Bowel Prep Use filters/filtered needles during dose preparation and injection.

Scanning hours post injection –Normally inject at 5pm and image at 7am HIRES/LEAP 15% Window 140keV SPECT –360 o –64 stops Anterior and Posterior –500K or 10 minutes –Head to pelvis –Lateral skulls

Findings Normal –Gallbladder –Intestine –Kidneys –Bladder –Pituitary gland –Testes –Thyroid –Salivary glands Abnormal –Hot spot late images cold center, hot ring early images –Uptake other than known tumors, inflammation, recent surgery sites, skin folds

False Readings False Positive –Areas of increased blood flow such as infection/inflammation False Negative –Usually brain, bone and small liver lesions

Survival Rate Extensive disease –Distant mets located –0-2% survival rate –Chemotherapy only Limited disease –No mets located –2 year survival rate –Chemotherapy and Radiation Therapy

Findings Verluma is a monoclonal antibody Fab fragment linked to 99mTc. Verluma identifies advanced-stage disease in patients with small-cell lung cancer (SCLC). The determination of disease stage has important prognostic and therapeutic implications. In the clinical trial involving 89 patients with confirmed SCLC, Tc-labeled Verluma accurately determined whether the disease was extensive or limited 82 percent of the time. If the test indicated extensive disease, the result was true in 94 percent of the patients. However, if the test indicated limited disease, it was less valuable as a diagnostic aid, failing to image tumors in some body organs in approximately 23 percent of the patients. Because of these false negative readings, additional standard diagnostic tests, such as a bone or CT scan or a bone marrow biopsy should be performed when limited disease is found. Verluma was approved August 20, this document was a handout at a biweekly inservice training at Beth Israel Deaconess Medical Center Nuclear Medicine Department led by Jeff Cone.

Findings Clinical experience with Tc-99m nofetumomab merpentan (Verluma) radioimmunoscintigraphy &dopt=Abstract &dopt=Abstract &dopt=Abstract

Return to the Table of Content